Home > News Center
 
Contact Us
Shanghai BravoBio Co., Ltd.
Add:Suite 14E, Building #5, Haifu Garden, 1365 Dongfang Road, Lujiazui Financial and Trade Zone, Shanghai 200127, China
Tel: +86 21 2025 5516
Fax: +86 21 2025 5517
Email: bd@bravobio.com
News Center
 
NIH grants up to $70M to develop new vaccine adjuvants
Oct. 2, 2014
 
NIH has forged 7 research agreements, which could total up to $70 million over 5 years, with academic and industry partners to development new adjuvant candidates. The grant will help look for compounds that can activate the adaptive immune system, which can provide long-term protection from infection by specific pathogens.
 
BravoBio spoke at 3rd International Biopharma Summit 2014
Oct. 21, 2014
 
The 3rd International Biopharma Summit 2014 was held in Wuhan from Oct 15th-16th, 2014. Dr.Wu was invited to give a speech about "Reduce the gap between China and western world by bridging collaboration".
 
FDA accepted Biologics License Application for Merck-Sanofi's hexavalent vaccine
Oct. 25, 2014
 
FDA recently accepted a Biologics License Application for the 6-in-1 vaccine made from Sinofi's Pentavalent (DTaP5-IPV-Hib) vaccine plus Merck's hep B. The application will undergo a standard 12-month review from its August filing date. In the Phase III trial, the subjects who received the hexavalent vaccine showed similar immune responses against the antigens covered by Sinofi's Pentacel plus Merck's hep B vaccine Recombivax.
 
Sanofi aiming to launch dengue vaccine in 2015
Nov. 10, 2014
 
With positive data from Latin American phase III trial, Sinofi plans to launch the dengue virus vaccine by the second half of 2015. Sanofi's candidate posted 95% efficacy against dengue hemorrhagic fever, and an 80.3% reduction in the risk of hospitalization.
 
Shantha launched pentavalent vaccine in India
Nov. 18, 2014
 
Shantha Biotechnics, a biotech company owned by Sanofi, launched its low-cost pentavalent vaccine (Shan5) in India, which protects children against diphtheria, tetanus, pertussis, Hib and hepatitis B. In this May, the vaccine also passed WHO prequalification. But in 2010, UNICEF and WHO recalled and destroyed about 24 million doses of Shan5 and disqualified Shantha as a supplier.
 
Cipla inked a deal with Serum Institute to make low cost vaccines
Nov. 21, 2014
 
Cipla, an Indian generics maker and also India's fourth-largest drugmaker, recently forged a deal with Serum Institute of India to make low cost vaccines and bring them to European market.
 
GSK and NIH got positive PhI data for Ebola vaccine trial
Dec. 10, 2014
 
GSK and NIH's National Institute of Allergy and Infectious Diseases (NIAID) recently got positive phase 1data for Ebola vaccine. In the 20-volunteer trial, half people received a lower-dose jab and half received a higher dose, with all 20 having developed Ebola antibodies and those who got the higher dose showing higher levels. Given the positive results, GSK and NIAID are going to expand the trial soon.
 
Merck Gardasil 9 won FDA approval
Dec. 14, 2014
 
FDA recently approved Gardasil 9, which prevents cervical, vulvar, vaginal and anal cancers caused by the four HPV types as well as additional 5 types--31, 33, 45, 52 and 58. In a study that involved about 14,000 females ages 16 through 26, Gardasil 9 was as effective as its predecessor Gardasil at blocking the four shared HPV types, and it was 97% effective in preventing cancers caused by the 5 additional types.
 
China approved AMMS Ebola vaccine candidate for clinical trials
Dec. 25, 2014
 
China recently approved the Ebola vaccine candidate which is developed by Academy of Military Medical Sciences (AMMS) for phase I trial. The trial may start as early as later this month, which would make the vaccine the third Ebola candidate ever tested in clinical trials behind the ones from GlaxoSmithKline and Merck /NewLink Genetics.
Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Next